197TiP A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Oncology"
DOI: 10.1016/j.annonc.2020.10.461
Abstract: s Annals of Oncology continue per protocol. Treatment with pembrolizumab/placebo will continue for up to 35 administrations (w2 years) or until disease progression, unacceptable toxicity, intercurrent illness that prevents further administration of treatment, or noncompliance.… read more here.
Keywords: bayer; merck; study; advisory consultancy ... See more keywords
A cross‐sectional study of psoriasis triggers among different ethno‐racial groups
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2017.04.1109
Abstract: Dr Bissonnette has received grants and research support, served as a consultant or received honoria from AbbVie, Amgen, Apopharma, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, GSK-Stiefel, Merck, Incyte, Janssen, Kineta, Leo Pharma, Merck, Novartis,… read more here.
Keywords: leo pharma; eli lilly; celgene; merck ... See more keywords
KEYLYNK-010: Phase III study of pembrolizumab (pembro) plus olaparib (OLA) vs enzalutamide (ENZA) or abiraterone (ABI) in ENZA- or ABI-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who had progression on chemotherapy (CTx)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz248.050
Abstract: Abstract Background In mCRPC pts unselected for homologous recombination deficiency (HRD), promising activity was seen with combination programmed death 1 inhibitor pembro and OLA in the phase 1b/2 KEYNOTE-365 study (NCT02861573), warranting further investigation in… read more here.
Keywords: abi enza; enza; pembro; genetics ... See more keywords
Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz255.063
Abstract: Abstract Background Pembro, a PD-1 inhibitor, has shown effective antitumor activity, durable responses, and survival benefit in pts with advanced melanoma. Len—a potent inhibitor of VEGF receptors 1-3, FGF receptors 1-4, PDGF receptor α, RET,… read more here.
Keywords: pembro; advisory consultancy; merck; novartis ... See more keywords
Immunogenicity of Inactivated Varicella Zoster Vaccine (ZVIN) in Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) Recipients
Sign Up to like & getrecommendations! Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx162.141
Abstract: Abstract Background Recipients of auto-HSCT have an increased risk of herpes zoster (HZ) infection; however, live attenuated varicella-zoster virus (VZV) vaccine is contraindicated in these patients. In this pivotal Phase III study (V212-001; NCT01229267) inactivated… read more here.
Keywords: merck; vaccine; auto hsct; placebo ... See more keywords
709. Activity of Key β-Lactam Agents Against Gram-Negative Bacilli From ICU Patients with Lower Respiratory Tract Infections, SMART United States 2015–2017
Sign Up to like & getrecommendations! Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.716
Abstract: Abstract Background Relebactam (REL), formerly MK-7655, is a β-lactamase inhibitor of class A and C β-lactamases that is in clinical development in combination with imipenem (IMI). In this study, we evaluated the activity of IMI/REL… read more here.
Keywords: employee; united states; merck; imi rel ... See more keywords
Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2022.22133
Abstract: BACKGROUND: Renal cell carcinoma (RCC) is associated with a high risk of recurrence. Although RCC has been shown to impose a substantial burden on patients, little is known about the incremental clinical and economic burden… read more here.
Keywords: high risk; recurrence; merck; epidemiology ... See more keywords